Clinical Trials Logo
  1. Home
  2. Hemolytic Anemia
  3. NCT00971984
  4. Details
NCT00971984 Clinical Trial

Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia in Northern Israel

Hemolytic Anemia Clinical Trial

Official title:
Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia in Northern Israel

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00971984
Other study ID # 0074-09-EMC
Secondary ID
Status Completed
Phase N/A
First received September 3, 2009
Last updated August 30, 2015
Start date October 2009
Est. completion date April 2012

Study information
Verified date August 2015
Source HaEmek Medical Center, Israel
Contact n/a
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Observational

Clinical Trial Summary

The study intends to summarize the clinical and laboratory characteristics of children with hemolytic anemia diagnosed as having alpha thalassemia mutations.

Description:

Fifty children and adolescents diagnosed as having alpha thalassemia will be studied, the clinical characteristics and hematology analysis will be summarized.

Recruitment information / eligibility
Status Completed
Enrollment 50
Est. completion date April 2012
Est. primary completion date April 2012
Accepts healthy volunteers No
Gender Both
Age group N/A to 20 Years
Eligibility Inclusion Criteria:

- All the patients that were studied at the pediatric hematology unit ant the Ha'Emek Medical Center

Exclusion Criteria:

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Intervention

Other:
• Medical records summary
Summary of Medical files and laboratory results.

Locations
Country Name City State
Israel Pediatric Hematology Unit and Pediatric Dpt B - HaEmek Medical Center Afula

Sponsors (1)
Lead Sponsor Collaborator
HaEmek Medical Center, Israel

Country where clinical trial is conducted

Israel, 

Outcome
Type Measure Description Time frame Safety issue
Primary Analysis of the Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia Analysis of the Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia One year No
See also
  Status Clinical Trial Phase
Completed NCT00001729 - Combination Drug Therapy for Patients With Hepatitis C Phase 3
Completed NCT00110617 - Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients Phase 2
Active, not recruiting NCT05004259 - The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia Phase 1
Completed NCT00842621 - Long Term Effects of Erythrocyte Lysis N/A
Completed NCT02111590 - Immunoglobulin Dosage and Administration Form in CIDP and MMN N/A
Active, not recruiting NCT04610866 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat Phase 1/Phase 2